Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study
Nan Zhou, Xinyi Li, Mingyou Gao, Xiaofen Li, Sirui Tan, Qiancheng Hu, Zijian Lu, Xi Xiao, Tianhong Wang, Shunyu Zhang, Haiyan Luo, Cheng Yi, Yu Yang, Hongfeng Gou · 2025
Read Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study by Nan Zhou, Xinyi Li, Mingyou Gao, Xiaofen Li, Sirui Tan, Qiancheng Hu, Zijian Lu, Xi Xiao, Tianhong Wang, Shunyu Zhang, Haiyan Luo, Cheng Yi, Yu Yang, Hongfeng Gou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12663050.txt.
Description
Nan Zhou and co-authors review what happened when a taxane drug, alone or paired with immunotherapy, was used as second-line treatment for advanced bile duct cancer, in this 2025 real-world study. Options after first-line therapy fails are thin for biliary tract cancer. Nab-paclitaxel had shown hints of activity, and whether adding a PD-(L)1 blocker helps, especially in patients who never had one, was open.
The records came from West China Hospital, covering 84 patients treated between 2018 and 2023. Forty-one received chemotherapy plus immunotherapy; 43 received chemotherapy alone. Overall, median survival was 15.17 months and median time without progression 5.40 months, with responses in about a fifth of patients. The paper sets the two groups side by side on survival, response, and side effects, offering practical evidence where trial data are scarce.
Catalog record
| CREATOR | Nan Zhou, Xinyi Li, Mingyou Gao, Xiaofen Li, Sirui Tan, Qiancheng Hu, Zijian Lu, Xi Xiao, Tianhong Wang, Shunyu Zhang, Haiyan Luo, Cheng Yi, Yu Yang, Hongfeng Gou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |